Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
After finishing at $1.47 in the prior trading day, Immuneering Corp (NASDAQ: IMRX) closed at $1.48, up 0.68%. In other words, the price has increased by $0.68 from its previous closing price. On the day, 0.59 million shares were traded. IMRX stock price reached its highest trading level at $1.53 during the session, while it also had its lowest trading level at $1.38.
Ratios:
Our goal is to gain a better understanding of IMRX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 11.35 and its Current Ratio is at 11.35. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.05.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Needham on March 15, 2024, Reiterated its Buy rating but revised its target price to $15 from $20 previously.
Jefferies Downgraded its Buy to Hold on March 15, 2024, whereas the target price for the stock was revised from $16 to $3.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Apr 01 ’24 when Cormorant Asset Management, LP sold 400,000 shares for $2.90 per share. The transaction valued at 1,160,181 led to the insider holds 2,895,273 shares of the business.
Feinberg Peter bought 25,000 shares of IMRX for $63,713 on Mar 22 ’24. The Director now owns 111,766 shares after completing the transaction at $2.55 per share. On Mar 22 ’24, another insider, Brakewood Harold Eugene, who serves as the Chief Business Officer of the company, bought 3,900 shares for $2.57 each. As a result, the insider paid 10,015 and bolstered with 3,900 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IMRX now has a Market Capitalization of 43887032 and an Enterprise Value of -37863484.
Stock Price History:
The Beta on a monthly basis for IMRX is -0.68, which has changed by -0.8344519 over the last 52 weeks, in comparison to a change of 0.24191546 over the same period for the S&P500. Over the past 52 weeks, IMRX has reached a high of $11.92, while it has fallen to a 52-week low of $1.40. The 50-Day Moving Average of the stock is -60.76%, while the 200-Day Moving Average is calculated to be -77.43%.
Shares Statistics:
The stock has traded on average 708.28K shares per day over the past 3-months and 408460 shares per day over the last 10 days, according to various share statistics. A total of 29.27M shares are outstanding, with a floating share count of 20.89M. Insiders hold about 29.56% of the company’s shares, while institutions hold 37.97% stake in the company. Shares short for IMRX as of 1713139200 were 2730363 with a Short Ratio of 3.85, compared to 1710460800 on 2610384. Therefore, it implies a Short% of Shares Outstanding of 2730363 and a Short% of Float of 17.41.
Earnings Estimates
The dynamic stock of Immuneering Corp (IMRX) is currently attracting attention from 7.0 analysts actively involved in rating its market status.On average, analysts expect EPS of -$0.5 for the current quarter, with a high estimate of -$0.22 and a low estimate of -$0.59, while EPS last year was -$0.51. The consensus estimate for the next quarter is -$0.49, with high estimates of -$0.23 and low estimates of -$0.58.
Analysts are recommending an EPS of between -$0.93 and -$2.29 for the fiscal current year, implying an average EPS of -$1.89. EPS for the following year is -$1.92, with 7.0 analysts recommending between -$0.83 and -$2.62.
